Nan Chiang

Aspirin therapy inhibits prostaglandin biosynthesis without directly acting on lipoxygenases, yet via acetylation of cyclooxygenase 2 (COX-2) it leads to bioactive lipoxins (LXs) epimeric at carbon 15 (15-epi-LX, also termed aspirin-triggered LX [ATL]). Here, we report that inflammatory exudates from mice treated with omega-3 polyunsaturated fatty acid and aspirin (ASA) generate a novel array of bioactive lipid signals. Human endothelial cells with upregulated COX-2 treated with ASA converted C20:5 omega-3 to 18R-hydroxyeicosapentaenoic acid (HEPE) and 15R-HEPE. Each was used by polymorphonuclear leukocytes to generate separate classes of novel trihydroxy-containing mediators, including 5-series 15R-LX(5) and 5,12,18R-triHEPE. These new compounds proved to be potent inhibitors of human polymorphonuclear leukocyte transendothelial migration and infiltration in vivo (ATL analogue > 5,12,18R-triHEPE > 18R-HEPE). Acetaminophen and indomethacin also permitted 18R-HEPE and 15R-HEPE generation with recombinant COX-2 as well as omega-5 and omega-9 oxygenations of other fatty acids that act on hematologic cells. These findings establish new transcellular routes for producing arrays of bioactive lipid mediators via COX-2-nonsteroidal antiinflammatory drug-dependent oxygenations and cell-cell interactions that impact microinflammation. The generation of these and related compounds provides a novel mechanism(s) for the therapeutic benefits of omega-3 dietary supplementation, which may be important in inflammation, neoplasia, and vascular diseases.

The essential fatty acid eicosapentaenoic acid (EPA) present in fish oils displays beneficial effects in a range of human disorders associated with inflammation including cardiovascular disease. Resolvin E1 (RvE1), a new bioactive oxygenated product of EPA, was identified in human plasma and prepared by total organic synthesis. Results of bioaction and physical matching studies indicate that the complete structure of RvE1 is 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-EPA. At nanomolar levels, RvE1 dramatically reduced dermal inflammation, peritonitis, dendritic cell (DC) migration, and interleukin (IL) 12 production. We screened receptors and identified one, denoted earlier as ChemR23, that mediates RvE1 signal to attenuate nuclear factor-kappaB. Specific binding of RvE1 to this receptor was confirmed using synthetic [(3)H]-labeled RvE1. Treatment of DCs with small interference RNA specific for ChemR23 sharply reduced RvE1 regulation of IL-12. These results demonstrate novel counterregulatory responses in inflammation initiated via RvE1 receptor activation that provide the first evidence for EPA-derived potent endogenous agonists of antiinflammation.

Ischemic stroke triggers lipid peroxidation and neuronal injury. Docosahexaenoic acid released from membrane phospholipids during brain ischemia is a major source of lipid peroxides. Leukocyte infiltration and pro-inflammatory gene expression also contribute to stroke damage. In this study using lipidomic analysis, we have identified stereospecific messengers from docosahexaenoate-oxygenation pathways in a mouse stroke model. Aspirin, widely used to prevent cerebrovascular disease, activates an additional pathway, which includes the 17R-resolvins. The newly discovered brain messenger 10,17S-docosatriene potently inhibited leukocyte infiltration, NFκB, and cyclooxygenase-2 induction in experimental stroke and elicited neuroprotection. In addition, in neural cells in culture, this lipid messenger also inhibited both interleukin 1-β-induced NFκB activation and cyclooxygenase-2 expression. Thus, the specific novel bioactive docosanoids generated in vivo counteract leukocyte-mediated injury as well as pro-inflammatory gene induction. These results challenge the view that docosahexaenoate only participates in brain damage and demonstrate that this fatty acid is also the endogenous precursor to a neuroprotective signaling response to ischemia-reperfusion. Ischemic stroke triggers lipid peroxidation and neuronal injury. Docosahexaenoic acid released from membrane phospholipids during brain ischemia is a major source of lipid peroxides. Leukocyte infiltration and pro-inflammatory gene expression also contribute to stroke damage. In this study using lipidomic analysis, we have identified stereospecific messengers from docosahexaenoate-oxygenation pathways in a mouse stroke model. Aspirin, widely used to prevent cerebrovascular disease, activates an additional pathway, which includes the 17R-resolvins. The newly discovered brain messenger 10,17S-docosatriene potently inhibited leukocyte infiltration, NFκB, and cyclooxygenase-2 induction in experimental stroke and elicited neuroprotection. In addition, in neural cells in culture, this lipid messenger also inhibited both interleukin 1-β-induced NFκB activation and cyclooxygenase-2 expression. Thus, the specific novel bioactive docosanoids generated in vivo counteract leukocyte-mediated injury as well as pro-inflammatory gene induction. These results challenge the view that docosahexaenoate only participates in brain damage and demonstrate that this fatty acid is also the endogenous precursor to a neuroprotective signaling response to ischemia-reperfusion. Brain ischemia-reperfusion triggers lipid peroxidation that participates in neural injury (1Beal M.F. Curr. Opin. Neurol. 1996; 6: 661-666Crossref Scopus (384) and Docosahexaenoic acid used neural and of used neural and of in membrane phospholipids is released in brain ischemia Scopus Scopus and is to lipid Scopus Leukocyte infiltration and pro-inflammatory gene expression of stroke damage Scopus Scopus Scopus messengers that The of acid messengers Scopus Scopus ischemia-reperfusion is an and activation in and acid Scopus Scopus Brain Scopus These fatty released from membrane phospholipids Scopus fatty from fatty only is in the and the is that membrane and is of the of Scopus is in Scopus membrane Scopus and and neuronal signaling Scopus and in Scopus Scopus Scopus a messenger is in is to bioactive from in have identified in the docosanoids have identified in the Scopus and have to neuroprotective and the have the of the mouse brain to bioactive we used lipidomic in ischemia-reperfusion. The of this the that brain ischemia Scopus Scopus Brain Scopus and that during of endogenous of from and as Scopus Scopus neural cells neural and and neural from and and the from and and the and of and the of experimental in a of and in the and and and of ischemia and the of The and a and the to The from the and to the The and the that the in the and the of the the of the The of the and the to the to the The to from and the of a Scopus of the of damage. of damage. Thus, to in the of only as in the The this of brain and of the of the of the from the to the of the The and the and brain and In of the and and in The in and a The in a of the in and a to a and and stroke and in cells to cells in in in neural neural and as the cells and and and the and neuronal and of cells to in the of and and using and of in and of and using Scopus of and from to of cells and from cells and in and using a Leukocyte the of leukocyte infiltration 10,17S-docosatriene in mouse and of and of in the the and from the and The brain Scopus the brain in and and and of to a and a and and of to Leukocyte the and of The brain to in in a of and The in and in in The in in and in of of docosanoids in from the of The in and In and of in a a a in a to and a of to an a used and The to and to The and and the of Docosahexaenoic used of in to the of is of acid from brain membrane phospholipids and Scopus Scopus of ischemia the a brain in in stroke and in (1Beal M.F. Curr. Opin. Neurol. 1996; 6: 661-666Crossref Scopus (384) and the of of novel docosanoids in the during ischemia-reperfusion. of the Scopus and a novel 10,17S-docosatriene to of The of 10,17S-docosatriene and to a also and to Scopus in and In addition, a of the as of the is used as well as to cerebrovascular we brain of messengers is in the of in in triggers the of lipid Scopus Scopus the of docosanoids in the of during an stroke the of a from the generated from endogenous of in the of that the novel in and which and the a in to a of cyclooxygenase-2 Scopus and a of the and the of identified and lipidomic we also the of Scopus Scopus Brain Scopus that the the the and in the in and The of of inhibited generated in as the which also results that the of used in vivo the of and in mouse of and specific in and study in the the to the novel in the of In in infiltration, of 10,17S-docosatriene in a experimental that leukocyte in Scopus is the also the These the in the of pathways 10,17S-docosatriene and the The in both pathways is the lipidomic and Scopus Scopus of leukocyte infiltration in and The of leukocyte 10,17S-docosatriene in of of and induction of and Leukocyte Ischemic in infiltration, a major in brain ischemia-reperfusion damage Scopus Scopus 1996; Scopus Scopus infiltration is a that is the expression of and signaling Scopus messengers to of the in the Scopus Scopus Scopus 10,17S-docosatriene during brain infiltration, this the during of in the in of as a of we a 10,17S-docosatriene the of the brain is a of infiltration in the brain Scopus Scopus 1996; Scopus Scopus and is a only in the In addition, we both the and the from the stroke as well as from the and the acid and the of 10,17S-docosatriene inhibited the of and the both in the and in the the brain of also elicited of infiltration in the of this is that is the of the bioactive is that of of 10,17S-docosatriene generated in the in of leukocyte infiltration 10,17S-docosatriene in mouse and of and of of the of and of that brain as The to the of the In a in of the stroke from the of that is of of of 10,17S-docosatriene in of as as in of 10,17S-docosatriene The acid and in and as the which in in and in as in of In the of and In the and the of of of and and as of 10,17S-docosatriene and in mouse of and of of 10,17S-docosatriene the and the the and and of endogenous of 10,17S-docosatriene and that of 10,17S-docosatriene and a in in Ischemic in vivo of 10,17S-docosatriene in brain during we a the to the lipid messenger the of of the brain and and is cells in a The of the the of and damage The in of the 10,17S-docosatriene a to of the stroke of the mouse brain to a and as The of as well as that of the and 10,17S-docosatriene as damage the to 10,17S-docosatriene in stroke in from mouse is identified a and brain a in and and as an the the the of the to brain from of and NFκB in Brain gene expression is an of brain injury. NFκB is in Scopus Scopus as is which in the and a to Scopus pro-inflammatory gene expression is also a of the novel messenger we of NFκB and as well as and expression in the NFκB in the and the of 10,17S-docosatriene inhibited NFκB activation and and which lipid a of 10,17S-docosatriene and expression we in the and a of The of the precursor as well as inhibited expression and The of 10,17S-docosatriene also expression inhibited and NFκB activation and expression. mouse of of 10,17S-docosatriene the inhibited 10,17S-docosatriene and expression in and 10,17S-docosatriene inhibited this expression. NFκB inhibited acid in to in NFκB induction as 10,17S-docosatriene the in the lipid activates expression that of expression of inhibited 10,17S-docosatriene also a of the lipid induction of of of and NFκB in 10,17S-docosatriene pro-inflammatory gene signaling in neural cells in to These cells and neuronal Scopus NFκB, and 10,17S-docosatriene NFκB to a that of cells in a of 10,17S-docosatriene the of this that of The of 10,17S-docosatriene cells the of a which the in cells of a this Scopus the of of in of infiltration neural cells in to docosanoids in cells this to and that expression of in neural cells is that the to the of demonstrate as well as in neural cells in culture, 10,17S-docosatriene an of pro-inflammatory gene activation brain NFκB and we have the in brain ischemia-reperfusion the of stereospecific pathways that to the of novel the is the of the messenger and the pathway, which is in the of to the of the messengers The pathways have the and signaling that brain injury. In the of and during we the of messengers that in of Scopus These messengers additional neuroprotective in brain ischemia-reperfusion. results demonstrate that the novel 10,17S-docosatriene is a of infiltration and pro-inflammatory gene induction. novel messenger also pro-inflammatory gene activation in neural cells in 10,17S-docosatriene potently elicited in vivo the stroke is to in the of in brain of that have to and of the Scopus that the of generated which the generated from to leukocyte to brain and to leukocyte-mediated and brain damage. The from endogenous to lipid that this is of the of of 10,17S-docosatriene of that results from activation and Scopus Scopus as well as The endogenous brain of 10,17S-docosatriene that of a response of as to counteract leukocyte infiltration and pro-inflammatory gene induction the experimental the of of the of the generated docosanoids to neuroprotection. of 10,17S-docosatriene the during the of neuroprotection. of is brain leukocyte infiltration Scopus Scopus 1996; Scopus Scopus in an the brain and and to a to injury in brain ischemia-reperfusion and infiltration as well as the of the stroke of the which from Scopus we demonstrate that 10,17S-docosatriene inhibited infiltration and the stroke The of a a of that 10,17S-docosatriene is the and as well as which in the of additional in of the brain is a the of lipid peroxidation Scopus and brain cells a major of that fatty phospholipids and and the of the novel 10,17S-docosatriene the as the this during brain ischemia-reperfusion as a of infiltration as well as activation of and Scopus 10,17S-docosatriene bioactive of infiltration and of pro-inflammatory gene expression of the signaling to is is that the of 10,17S-docosatriene is from ischemia-reperfusion have to both the of the brain injury and experimental we have novel pathways that to to in and that a The of 10,17S-docosatriene the of a neuroprotective in Brain ischemia-reperfusion triggers lipid peroxidation that participates in neural injury (1Beal M.F. Curr. Opin. Neurol. 1996; 6: 661-666Crossref Scopus (384) and Docosahexaenoic acid used neural and of used neural and of in membrane phospholipids is released in brain ischemia Scopus Scopus and is to lipid Scopus Leukocyte infiltration and pro-inflammatory gene expression of stroke damage Scopus Scopus Scopus messengers that The of acid messengers Scopus Scopus ischemia-reperfusion is an and activation in and acid Scopus Scopus Brain Scopus These fatty released from membrane phospholipids Scopus fatty from fatty only is in the and the is that membrane and is of the of Scopus is in Scopus membrane Scopus and and neuronal signaling Scopus and in Scopus Scopus Scopus a messenger is in is to bioactive from in have identified in the docosanoids have identified in the Scopus and have to neuroprotective and the have the of the mouse brain to bioactive we used lipidomic in ischemia-reperfusion. The of this the that brain ischemia Scopus Scopus Brain Scopus and that during of endogenous of from and as Scopus Scopus neural cells neural and and neural from and and the from and and the and of and the of experimental in a of and in the and and and of ischemia and the of The and a and the to The from the and to the The and the that the in the and the of the the of the The of the and the to the to the The to from and the of a Scopus of the of damage. of damage. Thus, to in the of only as in the The this of brain and of the of the of the from the to the of the The and the and brain and In of the and and in The in and a The in a of the in and a to a and and stroke and in cells to cells in in in neural neural and as the cells and and and the and neuronal and of cells to in the of and and using and of in and of and using Scopus of and from to of cells and from cells and in and using a Leukocyte the of leukocyte infiltration 10,17S-docosatriene in mouse and of and of in the the and from the and The brain Scopus the brain in and and and of to a and a and and of to Leukocyte the and of The brain to in in a of and The in and in in The in in and in of of docosanoids in from the of The in and In and of in a a a in a to and a of to an a used and The to and to The and and from and as Scopus Scopus neural cells neural and and neural from and and the from and and the and of and the of experimental in a of and in the and and and of ischemia and the of The and a and the to The from the and to the The and the that the in the and the of the the of the The of the and the to the to the The to from and the of a Scopus of the of damage. of damage. Thus, to in the of only as in the The this of brain and of the of the of the from the to the of the The and the and brain and In of the and and in The in and a The in a of the in and a to a and and stroke and in cells to cells in in in neural neural and as the cells and and and the and neuronal and of cells to in the of and and using and of in and of and using Scopus of and from to of cells and from cells and in and using a Leukocyte the of leukocyte infiltration 10,17S-docosatriene in mouse and of and of in the the and from the and The brain Scopus the brain in and and and of to a and a and and of to Leukocyte the and of The brain to in in a of and The in and in in The in in and in of of docosanoids in from the of The in and In and of in a a a in a to and a of to an a used and The to and to The and and the of Docosahexaenoic used of in to the of is of acid from brain membrane phospholipids and Scopus Scopus of ischemia the a brain in in stroke and in (1Beal M.F. Curr. Opin. Neurol. 1996; 6: 661-666Crossref Scopus (384) and the of of novel docosanoids in the during ischemia-reperfusion. of the Scopus and a novel 10,17S-docosatriene to of The of 10,17S-docosatriene and to a also and to Scopus in and In addition, a of the as of the is used as well as to cerebrovascular we brain of messengers is in the of in in triggers the of lipid Scopus Scopus the of docosanoids in the of during an stroke the of a from the generated from endogenous of in the of that the novel in and which and the a in to a of cyclooxygenase-2 Scopus and a of the and the of identified and lipidomic we also the of Scopus Scopus Brain Scopus that the the the and in the in and The of of inhibited generated in as the which also results that the of used in vivo the the to the novel in the of In in infiltration, of 10,17S-docosatriene in a experimental that leukocyte in Scopus is the also the These the in the of pathways 10,17S-docosatriene and the The in both pathways is the lipidomic and Scopus Scopus of leukocyte infiltration in and The of leukocyte 10,17S-docosatriene in of of and induction of and Leukocyte Ischemic in infiltration, a major in brain ischemia-reperfusion damage Scopus Scopus 1996; Scopus Scopus infiltration is a that is the expression of and signaling Scopus messengers to of the in the Scopus Scopus Scopus 10,17S-docosatriene during brain infiltration, this the during of in the in of as a of we a 10,17S-docosatriene the of the brain is a of infiltration in the brain Scopus Scopus 1996; Scopus Scopus and is a only in the In addition, we both the and the from the stroke as well as from the and the acid and the of 10,17S-docosatriene inhibited the of and the both in the and in the the brain of also elicited of infiltration in the of this is that is the of the bioactive is that of of 10,17S-docosatriene generated in the in of leukocyte infiltration 10,17S-docosatriene in mouse and of and of of the of and of that brain as The to the of the In a in of the stroke from the of that is of of of 10,17S-docosatriene in of as as in of 10,17S-docosatriene The acid and in and as the which in in and in as in of In the of and In the and the of of of and and as of 10,17S-docosatriene and in mouse of and of of 10,17S-docosatriene the and the the and and of endogenous of 10,17S-docosatriene and that of 10,17S-docosatriene and a in in Ischemic in vivo of 10,17S-docosatriene in brain during we a the to the lipid messenger the of of the brain and and is cells in a The of the the of and damage The in of the 10,17S-docosatriene a to of the stroke of the mouse brain to a and as The of as well as that of the and 10,17S-docosatriene as damage the to 10,17S-docosatriene in stroke in from mouse is identified a and brain a in and and as an the the the of the to brain from of and NFκB in Brain gene expression is an of brain injury. NFκB is in Scopus Scopus as is which in the and a to Scopus pro-inflammatory gene expression is also a of the novel messenger we of NFκB and as well as and expression in the NFκB in the and the of 10,17S-docosatriene inhibited NFκB activation and and which lipid a of 10,17S-docosatriene and expression we in the and a of The of the precursor as well as inhibited expression and The of 10,17S-docosatriene also expression inhibited and NFκB activation and expression. mouse of of 10,17S-docosatriene the inhibited 10,17S-docosatriene and expression in and 10,17S-docosatriene inhibited this expression. NFκB inhibited acid in to in NFκB induction as 10,17S-docosatriene the in the lipid activates expression that of expression of inhibited 10,17S-docosatriene also a of the lipid induction of of of and NFκB in 10,17S-docosatriene pro-inflammatory gene signaling in neural cells in to These cells and neuronal Scopus NFκB, and 10,17S-docosatriene NFκB to a that of cells in a of 10,17S-docosatriene the of this that of The of 10,17S-docosatriene cells the of a which the in cells of a this Scopus the of of in of infiltration neural cells in to docosanoids in cells this to and that expression of in neural cells is that the to the of demonstrate as well as in neural cells in culture, 10,17S-docosatriene an of pro-inflammatory gene activation brain NFκB and expression. Brain the of Docosahexaenoic used of in to the of is of acid from brain membrane phospholipids and Scopus Scopus of ischemia the a brain in in stroke and in (1Beal M.F. Curr. Opin. Neurol. 1996; 6: 661-666Crossref Scopus (384) and the of of novel docosanoids in the during ischemia-reperfusion. of the Scopus and a novel 10,17S-docosatriene to of The of 10,17S-docosatriene and to a also and to Scopus in and In addition, a of the as of the is used as well as to cerebrovascular we brain of messengers is in the of in in triggers the of lipid Scopus Scopus the of docosanoids in the of during an stroke the of a from the generated from endogenous of in the of that the novel in and which and the a in to a of cyclooxygenase-2 Scopus and a of the and the of identified and lipidomic we also the of Scopus Scopus Brain Scopus that the the the and in the in and The of of inhibited generated in as the which also results that the of used in vivo the the to the novel in the of In in infiltration, of 10,17S-docosatriene in a experimental that leukocyte in Scopus is the also the These the in the of Leukocyte Ischemic in infiltration, a major in brain ischemia-reperfusion damage Scopus Scopus 1996; Scopus Scopus infiltration is a that is the expression of and signaling Scopus messengers to of the in the Scopus Scopus Scopus 10,17S-docosatriene during brain infiltration, this the during of in the in of as a of we a 10,17S-docosatriene the of the brain is a of infiltration in the brain Scopus Scopus 1996; Scopus Scopus and is a only in the In addition, we both the and the from the stroke as well as from the and the acid and the of 10,17S-docosatriene inhibited the of and the both in the and in the the brain of also elicited of infiltration in the of this is that is the of the bioactive is that of of 10,17S-docosatriene generated in the in in Ischemic in vivo of 10,17S-docosatriene in brain during we a the to the lipid messenger the of of the brain and and is cells in a The of the the of and damage The in of the 10,17S-docosatriene a to of the stroke The of and NFκB in Brain gene expression is an of brain injury. NFκB is in Scopus Scopus as is which in the and a to Scopus pro-inflammatory gene expression is also a of the novel messenger we of NFκB and as well as and expression in the NFκB in the and the of 10,17S-docosatriene inhibited NFκB activation and and which lipid a of 10,17S-docosatriene and expression we in the and a of The of the precursor as well as inhibited expression and The of 10,17S-docosatriene also expression of and NFκB in 10,17S-docosatriene pro-inflammatory gene signaling in neural cells in to These cells and neuronal Scopus NFκB, and 10,17S-docosatriene NFκB to a that of cells in a of 10,17S-docosatriene the of this that of The of 10,17S-docosatriene cells the of a which the in cells of a this Scopus the of of in of infiltration neural cells in to docosanoids in cells this to and that expression of in neural cells is that the to the of demonstrate as well as in neural cells in culture, 10,17S-docosatriene an of pro-inflammatory gene activation brain NFκB and expression. we have the in brain ischemia-reperfusion the of stereospecific pathways that to the of novel the is the of the messenger and the pathway, which is in the of to the of the messengers The pathways have the and signaling that brain injury. In the of and during we the of messengers that in of Scopus These messengers additional neuroprotective in brain ischemia-reperfusion. results demonstrate that the novel 10,17S-docosatriene is a of infiltration and pro-inflammatory gene induction. novel messenger also pro-inflammatory gene activation in neural cells in 10,17S-docosatriene potently elicited in vivo the stroke is to in the of in brain of that have to and of the Scopus that the of generated which the generated from to leukocyte to brain and to leukocyte-mediated and brain damage. The from endogenous to lipid that this is of the of of 10,17S-docosatriene of that results from activation and Scopus Scopus as well as The endogenous brain of 10,17S-docosatriene that of a response of as to counteract leukocyte infiltration and pro-inflammatory gene induction the experimental the of of the of the generated docosanoids to neuroprotection. of 10,17S-docosatriene the during the of neuroprotection. of is brain leukocyte infiltration Scopus Scopus 1996; Scopus Scopus in an the brain and and to a to injury in brain ischemia-reperfusion and infiltration as well as the of the stroke of the which from Scopus we demonstrate that 10,17S-docosatriene inhibited infiltration and the stroke The of a a of that 10,17S-docosatriene is the and as well as which in the of additional in of the brain is a the of lipid peroxidation Scopus and brain cells a major of that fatty phospholipids and and the of the novel 10,17S-docosatriene the as the this during brain ischemia-reperfusion as a of infiltration as well as activation of and Scopus 10,17S-docosatriene bioactive of infiltration and of pro-inflammatory gene expression of the signaling to is is that the of 10,17S-docosatriene is from ischemia-reperfusion have to both the of the brain injury and experimental we have novel pathways that to to in and that a The of 10,17S-docosatriene the of a neuroprotective in we have the in brain ischemia-reperfusion the of stereospecific pathways that to the of novel the is the of the messenger and the pathway, which is in the of to the of the messengers The pathways have the and signaling that brain injury. In the of and during we the of messengers that in of Scopus These messengers additional neuroprotective in brain ischemia-reperfusion. results demonstrate that the novel 10,17S-docosatriene is a of infiltration and pro-inflammatory gene induction. novel messenger also pro-inflammatory gene activation in neural cells in 10,17S-docosatriene potently elicited in vivo the stroke is to in the of in brain of that have to and of the Scopus that the of generated which the generated from to leukocyte to brain and to leukocyte-mediated and brain damage. The from endogenous to lipid that this is of the of The of 10,17S-docosatriene of that results from activation and Scopus Scopus as well as The endogenous brain of 10,17S-docosatriene that of a response of as to counteract leukocyte infiltration and pro-inflammatory gene induction the experimental the of of the of the generated docosanoids to neuroprotection. of 10,17S-docosatriene the during the of neuroprotection. of is brain leukocyte infiltration Scopus Scopus 1996; Scopus Scopus in an the brain and and to a to injury in brain ischemia-reperfusion and infiltration as well as the of the stroke of the which from Scopus we demonstrate that 10,17S-docosatriene inhibited infiltration and the stroke The of a a of that 10,17S-docosatriene is the and as well as which in the of additional in of the brain is a the of lipid peroxidation Scopus and brain cells a major of that fatty phospholipids and and the The of the novel 10,17S-docosatriene the as the this during brain ischemia-reperfusion as a of infiltration as well as activation of and Scopus 10,17S-docosatriene bioactive of infiltration and of pro-inflammatory gene expression of the signaling to is is that the of 10,17S-docosatriene is from ischemia-reperfusion damage. These have to both the of the brain injury and experimental we have novel pathways that to to in and that a The of 10,17S-docosatriene the of a neuroprotective in the of and